Histologically confirmed GBM with radiographic progression (Cohort B). These patients are permitted to have had prior therapy including surgery, radiation, Temozolomide, irinotecan and bevacizumab. [clinicaltrials_resource:c084df3af908581643be5511289a3eb8]

Histologically confirmed GBM with radiographic progression (Cohort B). These patients are permitted to have had prior therapy including surgery, radiation, Temozolomide, irinotecan and bevacizumab. [clinicaltrials_resource:c084df3af908581643be5511289a3eb8]

Inclusion Criteria [clinicaltrials_vocabulary:Inclusion-Criteria]
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
http://bio2rdf.org/clinicaltrials_resource:c084df3af908581643be5511289a3eb8

Histologically confirmed GBM with radiographic progression (Cohort B). These patients are permitted to have had prior therapy including surgery, radiation, Temozolomide, irinotecan and bevacizumab. [clinicaltrials_resource:c084df3af908581643be5511289a3eb8]

Inclusion Criteria [clinicaltrials_vocabulary:Inclusion-Criteria]
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
http://bio2rdf.org/clinicaltrials_resource:c084df3af908581643be5511289a3eb8
Bio2RDF identifier
c084df3af908581643be5511289a3eb8
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c084df3af908581643be5511289a3eb8
identifier
clinicaltrials_resource:c084df3af908581643be5511289a3eb8
title
Histologically confirmed GBM w ...... irinotecan and bevacizumab.
@en
inDataset
type
label
Histologically confirmed GBM w ...... 4df3af908581643be5511289a3eb8]
@en